Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
높은 성장
회사의 매출은 지난 3년간 꾸준히 성장해왔으며, 연평균 26.12%의 증가율을 기록했습니다.
이익 전환
회사의 실적이 흑자로 전환되어, 최근 연간 순이익은 미화 달러에 달합니다.
공정한 가치
회사의 최신 PE은 44.59로, 최근 3년 기준 중간 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 161.64M주이며, 전 분기 대비 13.73% 감소했습니다.
시장 활동 증가
회사는 투자자들의 관심이 높아져, 최근 20일간 회전율이 0.36입니다.